רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdftreatment of symptoms of the...
TRANSCRIPT
![Page 1: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/1.jpg)
טפולים לא הורמונליים בגיל המעבר
?למי זה מתאים
?איזה טפולים קיימים
2017-ר יוסף מאי "ד
![Page 2: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/2.jpg)
Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
•Cynthia A. Stuenkel, Susan R. Davis, Anne Gompel, Mary Ann Lumsden, M. Hassan Murad, JoAnn V. Pinkerton, and Richard J. Santen University of California, San Diego, Endocrine/Metabolism (C.A.S.), La Jolla, California 92093;
Monash University, School of Public Health and Preventive Medicine (S.R.D.), Melbourne 03004, Australia; Universite´ Paris Descartes, Hoˆ pitaux Universitaires Port Royal-Cochin Unit de Gyne´ cologie Endocrnienne (A.G.),
Paris 75014, France; University of Glasgow School of Medicine (M.A.L.), Glasgow G31 2ER, Scotland; Mayo Clinic, Division of Preventive Medicine (M.H.M.), Rochester, Minnesota 55905; University of Virginia, Obstetrics and
Gynecology (J.V.P.), Charlottesville, Virginia 22908; and University of Virginia Health System (R.J.S.), Charlottesville, Virginia 22903 Objective: The objective of this document is to generate a practice guideline for the management
and treatment of symptoms of the menopause. Participants: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Society. Evidence:
The Task Force developed this evidenced-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of
evidence. The Task Force commissioned three systematic reviews of published data and considered several other existing meta-analyses and trials. Consensus Process: Multiple e-mail communications, conference calls, and one
face-to-face meeting determined consensus. Committees of The Endocrine Society, representatives from endorsing societies, and members of The Endocrine Society reviewed and commented on the drafts of the guidelines. The
Australasian Menopause Society, the British Menopause Society, European Menopause and Andropause Society, the European Society of Endocrinology, and the International Menopause Society (co-sponsors of the guideline)
reviewed and commented on the draft. Conclusions: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the
climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of
menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screen women before initiating MHT for cardiovascular and breast cancer risk and
recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use ofMHT to prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients
should not useMHT. Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures. (J Clin Endocrinol Metab
100: 3975–4011, 2015) ISSN Print 0021-972X ISSN O
![Page 3: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/3.jpg)
חלון ההזדמנות של הטיפול ההורמונלי
![Page 4: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/4.jpg)
טפול מקומי לנרתיק
•Topical non-hormonal options should be the first-line treatment in women with a history of
breast cancer, particularly those receiving tamoxifen or aromatase inhibitors. Women with breast cancer who do not respond to
non-hormonal treatment may consider vaginalestrogens after discussion with the woman’s
oncology team and menopause specialist.
![Page 5: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/5.jpg)
טפולים לא הורמונליים לנרתיק
Vaginal bioadhesive moisturisers are a more physiological way of replacing vaginal secretions than vaginal gels such as K-Y GEL. They are
hydrophilic and rehydrate vaginal tissues, providing a reasonable alternative to vaginal estrogen. Lubricants should have similar osmolality and pH to that of physiological vaginal secretions.
![Page 6: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/6.jpg)
GYNOMUNAL® VAGINAL GEL
NON- HORMONAL SAFE AND EFFECTIVE MANAGAMENT OF
VAGINAL ATROPHY ASSOCIATED SIGNS AND SYMPTOMS
![Page 7: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/7.jpg)
Gynomunal Ingredients
Hyaluronic Acido Forms a moisturizing, non-sticky, invisible film
o natural support of epithelial formation
Vitamin E
o Lipid-soluble antioxidant concentrated in vaginal cell membranes
o Protects cell walls from free radicals damage
o Has anti-inflammatory properties
HOPS Extract(humulus lupulus
o Relief of pain and itching
![Page 8: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/8.jpg)
Liposomes: Long –Lasting Vaginal Hydration
![Page 9: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/9.jpg)
non-keratinized-אפיתל. 1 Epithel קרטיןללא שכבת ,.כמו בעור , קרןLamina-מתחתיה שכבה . 2 Propria ובה יש רשת ורידים
Venous, כוורת, דופןדקי Plexus ,וקצוות עצבים, ניקוז לימפה ./ העשרה . כלי הדם הנעשים גדושים בדם בזמן גירוי מיני
הלייזרהרחבה של רשת הורידים בעקבות Neovascularization לתת הסבר לשיפור עשויה
.Rejuvenationשל הנרתיק כ ,לובריקציה, הסיכוך
1+2 =Mucosa = Epithel + Lamina Propriaבתקופה המנופאוזה יכולה הרירית . מיקרון100-200כ
. מיקרון50לכלרדת
הקרובים סיבי רוחב מעגליים -Muscularis-שריר. 3ומחוצה להם סיבי (כטבעות סביב הנרתיק ) למוקוזהיותר יש . אין קו הפרדה ברור בין שתי שכבות סיבי השריר. אורך
כטבעת ) המעגלית(הצירקולריתהמגדירים את שכבת השריר ״ המייצר טונוס לנרתיק ויתכן שהשפעה עליו ספינקטר״
המונח מעליו ושליטה טובה לשופכןמייצרת תמיכה טובה יותר . יותר למתן שתן
Adventitia.4השכבה הפנימית של הנרתיק היא רקמת חיבור בלתי סדירה
. עושר כלי דם ועצבים, עם סיבים אלסטיים
![Page 10: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/10.jpg)
FemiLift Single Use Hygienic Vaginal Probe:
Y. Tadir
Alma Laser
![Page 11: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/11.jpg)
0 0+ 3 Months 6 Months
“Macro”: Vag. Rejuvenation
Process
![Page 12: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/12.jpg)
H&E staining.Vaginal mucosa before treatment (a, c)and 2 months after treatment (b, c).
the atrophic mucosa (epithelium) is very thin, formed by few layers of cells, and the epithelial-connective Junction.
The epithelium appears much thicker, constituted by many layers with visible largeintermediate and shedding superficial cells.
The underlying connective tissue is providedwith papillae indenting the epithelial-connective junction.
Comparative microphotographs (before and 2 months after
treatment) of atrophic vaginal mucosa demonstrate striking structural recovery at two months after treatment in all the patients
(Paper #1)
Jan.2015
![Page 13: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/13.jpg)
TWO PAPERS at the same time: Italy – (Using DEKA CO2 LASER)1. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional CO2 laser treatment. Zerbinati, et al. Laser Med. Sci.
Squamous Epitheium: Restoration, with a significant storage of glycogen in the epithelial cells.
lamina propria, active fibroblasts synthesized. New components of the extracellular matrix including collagen and ground substance (extrafibrillar matrix) molecules.
Differently from atrophic mucosa, newly-formed papillae of connective tissue in the epithelium and typical blood capillaries penetrating inside the papillae, were observed.
These findings clearly coupled with striking clinical relief from symptoms.
Jan.2015
2. An Ex. Vivo study: Salvatore, et al. Menopause.
![Page 14: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/14.jpg)
חלופות לטיפול הורמונלי
טיפול לא תרופתיטיפול תרופתי
"(טבעי)"
![Page 15: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/15.jpg)
טיפול תרופתי לא הורמונאליSSRI( ציפרלקס, סרוקסאט)
SNRI( ויאפקס, אפקסור)
GABAPENTIN (נאורונטין)
CIMIDONA (black Kohosh)
![Page 16: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/16.jpg)
alternatives to HRTA recent meta-analysis of a few randomisedcontrolled trials has shown a marginal benefit of
clonidine (centrally-acting alpha adrenergic agonist) over placebo, for hot flushes.(25-50-75 mcg X2/d).
A significant amount of evidence exists for the efficacy of SSRI’s such as fluoxetine (prisma, flutin, prozac) and paroxetine (seroxate) in treating vasomotor symptoms; the most convincing data are for the SNRI (venlafaxine-efexor, viepax) at a dose of 37.5 mg bd in cancer survivors. The most common side effect, nausea, limits the usefulness of this agent
.
![Page 17: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/17.jpg)
Powerpoint Templates Page 17
NICE
National Institute for Health and Care Excellence
הנחיות ועצות לשיפור שמספק גוף ציבורי בלתי תלוי הוא
.באנגליההמצב הבריאותי והסוציאלי
י מועצה בלתי תלויה של מומחים "ההמלצות שנכתבו ע
. מיועדות לכל סוגי היועצים הרפואיים ולמטופלים, בתחום
![Page 18: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/18.jpg)
Recent high quality evidence shows
that selected antidepressants are
equivalent to very low dose estrogen
for vasomotor symptoms and sleep,
and gabapentin (anti-epileptic drug) has a
similar efficacy.
.
![Page 19: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/19.jpg)
![Page 20: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/20.jpg)
יעילות טיפולים תרופתיים לא הורמונליים
SeroxatEffexor XR Viepax XR
Cipralex
![Page 21: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/21.jpg)
תופעות לוואי
![Page 22: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/22.jpg)
"טבעי"ל יפוט
אסטרוגנים-פיטו
שחור-קוהוש
דיקור
![Page 23: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/23.jpg)
Feb. 2015
![Page 24: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/24.jpg)
![Page 25: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/25.jpg)
OH
HO
Phytoestrogens
פיטואסטרוגנים
![Page 26: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/26.jpg)
2014
2014
![Page 27: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/27.jpg)
![Page 28: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/28.jpg)
PhytoestrogensData from some of the better researched phytoestrogen
containing preparations appear to demonstrate some
benefits, not only for symptom relief, but also on the
skeleton and cardiovascular system.
Efficacy for vasomotor symptom relief is lower than with
traditional HRT (maximally 60% symptom reduction
compared to 90–100% with traditional HRT).
There are as yet no hard data on major outcome
measures such as coronary heart disease and fractures.
![Page 29: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/29.jpg)
Soy food linked to prolonged survival in certain breast cancer patients
Zhang FF, et al. Dietary Isoflavone Intake and All-Cause Mortality in Breast
Cancer Survivors: the Breast Cancer Family Registry. Cancer. Published online
March 6, 2017. doi: 10.1002/cncr.30615Univadis08/03/20175 viewsNew research indicates that dietary soy products are safe and even beneficial for women diagnosed with breast cancer. Published online in the journal Cancer , the findings may help resolve the long-running debate surrounding soy’s potential link to breast cancer outcomes as a result of its oestrogen-like properties.
Isoflavones, the component of soy with oestrogen-like
properties, have been shown to slow the growth of breast cancer cells in laboratory studies, and epidemiological analyses in
women with breast cancer found links between higher isoflavone intake and reduced mortality.
![Page 30: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/30.jpg)
The new study examined the relationship between dietary intake of isoflavones and death from any cause in 6,235 American and
Canadian women diagnosed with breast cancer. Over a median
follow-up of nine years, women with breast cancer who
consumed high amounts of isoflavones had a 21 per cent lower risk of dying than women who consumed low amounts. This decrease was largely confined to women with hormone receptor-negative tumours and women who were not treated with anti-oestrogen therapy. However,
other research has suggested that the isoflavones may reduce the effectiveness of hormone therapies for breast cancer.
In contrast, high isoflavone intake was not associated
with greater mortality among women receiving hormonal therapy.
![Page 31: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/31.jpg)
Explain that there is some evidence that isoflavonesmay relieve vasomotor symptoms.
However,
explain that:
-Preparations vary
-The safety of different preparations is uncertain and
interactions with other drugs have been reported.
![Page 32: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/32.jpg)
….specific phytoestrogen supplementations
(EXAMP: ALTERNA, MAGNOLIA) were
associated with modest reductions in the
frequency of hot flashes and vaginal dryness
but no significant reduction in night sweats.
Conclusions
![Page 33: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/33.jpg)
Black Cohosh
קוהוש שחור
(Cimicifuga Racemosa)
![Page 34: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/34.jpg)
אינדקסקופרמן
גלי : תסמיני גיל המעבר11מדד מספרי הבודק
, מלנכוליה, עצבנות, נדודי שינה, כאבים, חום
, כאבי מפרקים או כאבי שרירים, חולשה, סחרחורת
דפיקות לב ותחושה שחרקים זוחלים , כאבי ראש
(. (formicationלעור מעל או מתחת
והפרעות אורוגניטלייםבהמשך נוספו תסמינים
סימפטום מדורג על פי חומרת כל . ביחסי מין
3= אין סימפטומים ו= 0כאשר )סימפטומים
הציון . והסכום הכולל מחושב, (החמורים ביותר
.נקודות51המקסימאלי הוא
![Page 35: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/35.jpg)
MRS – menopausal rating scale
psychological symptoms: 0 to 16 scoring points ( 4 symptoms: depressed, irritable, anxious, exhausted)
somato-vegetative symptoms: 0 to 16 points (4 symptoms: sweating/flush, cardiac complaints, sleeping disorders, joint & muscle complaints)
urogenital symptoms: 0 to 12 points (3 symptoms: sexual problems, urinary complaints, vaginal dryness).
![Page 36: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/36.jpg)
RemifemineR
0
5
10
15
20
25
30
35
0 2 4 8 12
PLACEBO
REMIFEMINE
Weeks
Stoll W. Therapeutikon 1:23, 1987
=Black Kohosh
השפעה על תסמיני המנופאוזה
![Page 37: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/37.jpg)
שחור-תכשירי קוהוש
![Page 38: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/38.jpg)
A 2012 Cochrane review analyzed 16 RCTs of 2,027
perimenopausal or postmenopausal women treated with black
cohosh using a median daily dose of 40mg for a mean duration
of 23 weeks. There was no significant difference between
black cohosh and placebo in the frequency of hot flashes. Data
on safety were also inconclusive. The authors concluded that, at
this time, there is insufficient evidence to support the use of
black cohosh for menopausal symptoms. Level I evidence
Black Cohosh
![Page 39: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/39.jpg)
Explain that there is some evidence that
black cohosh may relieve vasomotor
symptoms.
However,
explain that:
-Preparations vary
-The safety of different preparations is uncertain and
interactions with other drugs have been reported.
![Page 40: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/40.jpg)
![Page 41: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/41.jpg)
![Page 42: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/42.jpg)
Selective ER modulators ?
Modulation of serotonergic pathways ?
Antioxidant and anti-inflammatory effects ?
![Page 43: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/43.jpg)
סימידונה• Product characteristics:• Composition Active substance: Dry extract, from
Cimicifugae rhizoma (Black cohosh) Excipients: Povidone,cellulose microcrystalline, lactose monohydrate, magnesiumstearate, silica colloidal anhydrous, croscarmellose sodium.
• Information for diabetics : 1 tablet contains 0.004carbohydrate exchange units. The product containslactose (44 mg per tablet).
• Galenic Form and Active Substance per Unit: Tablet. 6.5mg dry extract (Ze 450) from Cimicifugae rhizoma der4.5 – 8.5:1, extraction solvent 60% ethanol (V/V).
• Indications: For the alleviation of complaints duringmenopause (hot flashes, excessive perspiration, sleepdisorders, nervousness and depressive moods).
![Page 44: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/44.jpg)
שבועות12, נשים180
![Page 45: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/45.jpg)
Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: A prospective, randomized trial
Advances in TherapyMarch 2007, Volume 24, Issue 2, pp 448–461
•Authors Mesut Oktem•Derya Eroglu et al.
1.Department of Obstetrics and GynecologyBaskent University School of Medicine MaltepeAnkaraTurkey
2.Department of PsychiatryTurkey
The objective of this study was to evaluate the efficacy of fluoxetine and black cohosh in the treatment of women with postmenopausal symptoms. A total of 120 healthy women with menopausal symptoms were recruited to this prospective study with a follow-up period of 6 mo. They were randomly assigned to 1 of 2 groups and were treated with fluoxetine or black cohosh. After entry into the study, patients were examined at the first, second, third, and sixth months of the treatment period. The women kept diaries in which they reported the daily number and intensity of hot flushes and night sweats. In addition, at the beginning and end of the third month, they completed questionnaires consisting of a modified Kupperman Index, Beck’s Depression Scale, and a RAND-36 Quality-of-Life Questionnaire. Statistically significant differences were noted in the Kupperman Index and Beck’s Depression Scale at the end of the third month in both groups compared with baseline values. In the black cohosh group, the Kupperman Index decreased significantly compared with that in the fluoxetine group by the end of the third month. On the other hand, in the fluoxetine group, Beck’s Depression Scale decreased significantly compared with that in the black cohosh group. Monthly scores for hot flushes and night sweats decreased significantly in both groups; however, black cohosh reduced monthly scores for hot flushes and night sweats to a greater extent than did fluoxetine. At the end of the sixth month of treatment, black cohosh reduced the hot flush score by 85%, compared with a 62% result for fluoxetine. By the sixth month of the study, 40 women had discontinued the study—20 (33%) in the fluoxetine group and 20 (33%) in the black cohosh group.
Compared with fluoxetine, black cohosh is more effective for treating hot flushes and night sweats. On the other hand, fluoxetine is more effective in improvements shown on Beck’s Depression Scale.
![Page 46: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/46.jpg)
1
Cimidona – excellent safety profile
![Page 47: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/47.jpg)
Ze 450 – Study overview
47
![Page 48: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/48.jpg)
Safety – Focus on the estrogen receptor
48
Cimicifuga extract Ze 450 showed in vitro an inhibition of proliferation in a MCF-7 human breast cancer cell line2
Henneicke-von Zepelin et al.4 were able to show by means of a pharmacoepidemiologic observational retrospective cohort study that
there is probably no higher risk for breast cancer recurrence for women having black cohosh treatment compared to untreated women
1Viereck, V. et al. TRENDS in Endocrinology and Metabolism (2005);16; 5: 214-221
2Garita-Hernandez, M. et al. PlantaMed (2006); 72: 317-323
3Burdette JE, et al. J Agric Food Chem (2003); 51: 5661-5670
4Rhuy MR, et al. J Agri Food Chem (2006); 54: 9852-9857
5Hui Z, et al. Journal of Ethnopharmacology(2012); 142;3: 769-775
![Page 49: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/49.jpg)
Mode of action of Ze 450
49
Cimicifuga extracts do not have an estrogenic effect 1,2,3
There is a great body of evidence that Cimicifuga extracts have central (neuro-hormonal) effects 1,2,3,4,5
Several studies suggest a partial agonistic action at the serotonin receptors (5-HT), the dopamine receptor and the μ-opiate
receptor 3,4 – for the latter the clinical relevance is questionable
1Viereck, V. et al. TRENDS in Endocrinology and Metabolism (2005);16; 5: 214-221
The mode of action of Cimicifuga is not yet enlightened into detail
2Garita-Hernandez, M. et al. PlantaMed (2006); 72: 317-323
3Burdette JE, et al. J Agric Food Chem (2003); 51: 5661-5670
4Rhuy MR, et al. J Agri Food Chem (2006); 54: 9852-9857
5Hui Z, et al. Journal of Ethnopharmacology(2012); 142;3: 769-775
![Page 50: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/50.jpg)
Schellenberg et al. 2012 – Summary
50
Ze 450 is a effective and well-tolerated non-hormonal alternative to HRT
Schellenberg R., Saller R., Hess L., Melzer J., Zimmermann C., Drewe J., Zahner C. Evidence-Based Complementary and Alternative Medicine (
Dose-dependent effect of Ze 450
Both, 6.5 and 13 mg decreased significantly the severity of climacteric symptoms in the total KMI, compared to placebo
For patients with severe symptoms (KMI > 34) only the high dose (13 mg Ze 450) was effective
General Quality of Life increased also dose dependently
![Page 51: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/51.jpg)
Lopatka et al. 2007 – Reduction of the MRS II score
51
Overall MRS IIp < 0.0001
* MRS = Menopausal Rating Scale II
Already after one month, Ze 450 alleviates the menopausal symptoms reaching significance after 4 months of treatment
![Page 52: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/52.jpg)
Drewe et al. 2013 – Observational long-term study
52
442 women, mean age 52.3 yrs., with menopausal complaints
9 months (3 + 6 months)
Treatment with 13 mg Ze 450/d for 3 months Further 6 months treatment either with 13mg/d or switch to 6.5 mg/d
1st : Changes in total Kupperman Index (KMI)2nd : Analysis of each subitem of the KMI
Drewe et al., Phytomedicine (2013)
Treatment of unselected patients with 13 mg or 6.5 mg Ze 450, under daily practice condition
![Page 53: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/53.jpg)
Lopatka et al. 2007 – Improvement of the sub-items
53
Effect of Ze 450 on the MRS II sub-item score
Baseline
1 month
4 month
Ze 450 significantly reduces the severity of every symptom after four months of treatment
The improvement was indicated already after one month of treatment
![Page 54: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/54.jpg)
Drewe et al. 2013 – Reduction of the KMI
54
Significant reduction of the Kupperman Index (KMI) after 3 and 9 months treatment
After 3 months treatment with 13mg Ze 450 the KMI was significantly reduced
The extension treatment further decreases the KMI significantly - independent of the dose
Baseline
HD (13 mg)
LD (6.5 mg)
n = 238 n = 131n = 372
![Page 55: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/55.jpg)
Cimidona-נתוני בטיחות מהעלון לרופא
Ze450כל טבלייה מכילה במדויק את אותה כמות של החומר הפעיל בסימידונה•( השחורמהקוהושהממוצה )
לא צפויות אינטראקציות בין תרופתיות •
postנתוני מחקרים וכן מידע )GIמרבית תופעות הלוואי המדווחות הינן של •marketing מתוכן , ל"ת5.4%-מטופלות מעידים על אחוז של כ2800-שנאספו על כ
ויתר המקרים לא שויכו ספציפית לטיפול עם , היו קלות ולא דרשו הפסקת טיפול97%(סימידונה
:אך ההנחיות הן , מסימידונהלא דווחו מקרים חריגים של נזקים בכבד שנגרמו •
ידועהכבדיתמחלה /אין לתת למטופלות עם נזק–
צבע , חולשה ואובדן תאבון, עייפות חריגה:יש להפסיק מתן במקרים של –סימנים אשר עשויים להצביע –שתן או צואה כהים , צהוב בעור או בקרנית
על נזק כבדי
או אם יש , בחזהתחושת מתח יש להתייעץ עם רופא במקרים של תחושת נפיחות או •הכתמה דמית או דימום מחזורי , דימום
55.1Data on File – Zeller Safety Data
.2Cimidona PI as approved by the Israeli MOH
![Page 56: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/56.jpg)
Efficacy of Ze 450 – Summary
56
Ze 450 dose dependently decreases the whole set of menopausal symptoms
Mild to moderate symptoms can successfully be treated with 6.5mg of Ze 450; severe symptoms can be treated with
13mg
Ze 450 reduces the symptoms already after one month; symptoms are decreased further with thecontinuation of the
treatment (6 weeks treatment recommended in the SPC)
Patients may successfully be switched from HRT to Ze 450
![Page 57: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/57.jpg)
תודה על ההקשבה
![Page 58: רבעמה ל יגב םיילנומרוה אל םילופטžאי.pdfTreatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline Cynthia A. Stuenkel, Susan](https://reader034.vdocuments.site/reader034/viewer/2022042222/5ec870f105ffa765be0918e5/html5/thumbnails/58.jpg)
COMPARISON OF NEW MINIMALLY INVASIVE ER:YAG LASER TREATMENT AND HORMONAL REPLACEMENT THERAPY IN THE TREATMENT OF VAGINAL ATROPHYGaspar Adrian (AR) [1][1] University of Mendoza
TITLE.AUTHOR/S.ABSTRACT.
Objective: The objective of this study was to comp are the efficacy and safety of two minimally invasive procedures for treatment of vaginal atrophy; a new Er:YAG laser procedure and hormonal replacement therapy with estriol. Method: 50 vaginal atrophy patients were randomly divided in two equal groups. Group A patients were
submitted to long term estriol therapy: 0.5 mgr/day 3 times a week during 2 weeks, followed with the same estriol dosage twice a week for 4 weeks. B group patients firstly got the same short term estriol
therapy for 2 weeks, followed with 3 sessions of ErYAG laser treatment, with 3 weeks interval between
the sessions. Therapy efficacy was measured using maturation value, pH value, VAS scores for atrophy
symptoms: Dyspareunia, Dryness, Irritation and Leukorrhea. On 6 patients from each group biopsies
were taken (before and 3 months post-op). Follow-ups were at 1 month, 3 months and 6 months after the therapy.
Results: Both groups showed improvement in atrophy, but laser therapy showed better and longer lasting effects. Maturation value in A group improved from 22,5 points to 24,7 points at 6 months follow-up. In comparison to that B group improvements was from 20,8 points to 47,9 points. pH value improved at 3 months for 7,2% in A group, and for 17,6% in B group. Dyspareunia in A group improved for 48%, and in B group for 72%; Dryness in A group for 68%, in B group for 76%; Irritation in A group for 48%, in B group for 60% and Leukorrhea in A group for 81%, while in B group for 94%. Both groups tolerated the therapy well and adverse effects were mild and transient.
Conclusions: Hormonal replacement therapy is considered to be the first choice for vaginal atrophy, but this new minimally invasive Er:YAG laser procedure seems to be safe and efficacious alternative with potential to offer to vaginal atrophy patients longer period of symptom free life.
58